This Biotech Fund Sold $8 Million, Yet Remains Bullish on Terns
A biotech fund reduced its Terns Pharmaceuticals position by about $8 million last quarter. Despite the sale, the the...
Assess which market exposure—Total Market or SP 500—offers more durable performance for retirement spending and resilience.
28,477 articlesA biotech fund reduced its Terns Pharmaceuticals position by about $8 million last quarter. Despite the sale, the the...
BioCryst faces a pivotal year. This practical guide breaks down what biocryst (bcrx) 2026 earnings could mean for inv...
Political headlines move markets—and your finances. This guide shows how statements like donald trump publicly blames...
Two pharma giants are wighting for a leadership position in immunology. This piece explains why Johnson Johnson hopes...
When celebrities make their relationship public, it isn’t just headlines that change. Janel Parrish Sasha Farber prov...
U.S. retirees are eyeing Panama’s beach towns as costs rise at home. The question remains: can $600,000 sustain a rel...
When markets wobble, a single number can guide decisions. This article explains why beta matters and how a low-volati...
AI rumors can move markets, but what matters is the real impact on Nvidia's fundamentals. This guide explains how to ...
AI momentum is reshaping the market today. We break down what’s moving stocks, why tech names are rallying, and how i...
Choosing between SCHD and VIG comes down to your goals: current income vs. steady growth. This guide breaks down how ...
A new income-focused ETF challenger has pushed past JEPI by roughly 42 percentage points since its October 2023 debut...
A family estate dispute escalates after a stepmother allegedly withholds $500,000 from a father's will, prompting leg...